Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 5:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: RRx-001 Clear all
Terminated Phase 2 Interventional Results available

RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy

NCT02452970
View directory record Official record
Conditions
Cholangiocarcinoma
Interventions
RRx-001, Gemcitabine and cisplatin
Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 4, 2026, 5:56 AM EDT
Completed Phase 2 Interventional Results available

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

NCT02489903
View directory record Official record
Conditions
Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neuroendocrine Tumors, Ovarian Epithelial Cancer
Interventions
RRx-001, Cisplatin, Etoposide, Carboplatin, Irinotecan, Vinorelbine, Doxil, Gemcitabine, Taxane, Paclitaxel, Nab-Paclitaxel, Pemetrexed
Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
10
States / cities
Palo Alto, California • West Haven, Connecticut • South Bend, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Sep 4, 2026, 5:56 AM EDT
Completed Phase 1 Interventional

RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas

NCT02871843
View directory record Official record
Conditions
Glioblastoma, Oligodendroglioma, Anaplastic Oligodendroglioma
Interventions
RRx-001 dose escalation with TMZ + RT, Radiation, Fixed dose Temozolomide (75 mg/m2), TMZ Maintenance
Drug · Radiation
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
San Francisco, California • New Brunswick, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2022 · Synced Sep 4, 2026, 5:56 AM EDT
Active, not recruiting Phase 2 Interventional

RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer

NCT05966194
View directory record Official record
Conditions
Oral Mucositis
Interventions
RRx-001, Intensity Modulated Radiation Therapy (IMRT), Cisplatin for injection 100 mg/m2
Drug · Radiation
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
14
States / cities
Gilbert, Arizona • Tucson, Arizona • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 4, 2026, 5:56 AM EDT
Completed Phase 1 Interventional

A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab

NCT02518958
View directory record Official record
Conditions
Malignant Solid Tumor, Lymphoma
Interventions
RRx-001, Nivolumab
Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Sep 4, 2026, 5:56 AM EDT
Terminated Phase 3 Interventional

RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer

NCT03699956
View directory record Official record
Conditions
Carcinoma, Small Cell Lung
Interventions
RRx-001 + eLOOP Device, Cisplatin/carboplatin plus etoposide
Combination Product · Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
18
States / cities
Denver, Colorado • Orange City, Florida • Orlando, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Sep 4, 2026, 5:56 AM EDT
Terminated Phase 1 Interventional

RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors

NCT04525014
View directory record Official record
Conditions
Brain Tumor, Recurrent, Brain Tumor, Pediatric, Central Nervous System Neoplasms, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
RRx-001, Temozolomide, Irinotecan
Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
1 Year to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 4, 2026, 5:56 AM EDT
Completed Phase 1 Interventional Results available

Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects

NCT01359982
View directory record Official record
Conditions
Malignant Solid Tumor, Lymphomas
Interventions
RRx-001
Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
La Jolla, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Sep 4, 2026, 5:56 AM EDT
Completed Phase 1 Interventional

Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases

NCT02215512
View directory record Official record
Conditions
Brain Metastases
Interventions
RRx-001 + WBRT
Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
5
States / cities
Santa Monica, California • Ann Arbor, Michigan • Jackson, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 4, 2026, 5:56 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer

NCT05566041
View directory record Official record
Conditions
Carcinoma, Small Cell Lung
Interventions
RRx-001 + eLOOP Device, Cisplatin/carboplatin plus etoposide
Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Tampa, Florida • Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 4, 2026, 5:56 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer

NCT02096354
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
RRx-001, Regorafenib, Irinotecan
Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
5
States / cities
La Jolla, California • Stanford, California • Honolulu, Hawaii + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 4, 2026, 5:56 AM EDT
Terminated Phase 1 Interventional

A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001

NCT02096341
View directory record Official record
Conditions
Malignant Solid Tumor, Lymphomas
Interventions
RRx-001
Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Sep 4, 2026, 5:56 AM EDT
Terminated Phase 1 Interventional

RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)

NCT02801097
View directory record Official record
Conditions
Malignant Solid Tumor, Metastatic Cancer, Advanced Cancer
Interventions
RRx-001, Irinotecan
Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Sacramento, California • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Sep 4, 2026, 5:56 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers

NCT03515538
View directory record Official record
Conditions
Oral Mucositis
Interventions
RRx-001, Cisplatin for injection, Radiation Therapy
Drug · Radiation
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
12
States / cities
Santa Monica, California • Denver, Colorado • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2024 · Synced Sep 4, 2026, 5:56 AM EDT